Stockreport
Immunomedics Announces Multiple Clinical and Preclinical Collaborations With Prominent Cancer Research Institutions
Last immunomedics earnings: 8/23 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations: immunomedics.com/2017/immunomedics-announces-presentations-investor-event-2017-san-antonio-breast-cancer-symposium
PDF
Clinical Collaboration with Yale University to Evaluate Sacituzumab Govitecan in Two Phase 2 Studies in Endometrial and Cervical Cancers Research Collaborations with Yale University, Memorial Sloan Kettering Cancer Center, and Fred Hutchinson Cancer Research Center to Further Investigate Sacituzumab Govitecan and Labetuzumab Govitecan in Preclinical Cancer Models MORRIS PLAINS, N.J., July 30, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced a collaboration with the Yale Cancer Center at the Yale University School of Medicine to evaluate Immunomedics’ lead ADC product candidate, sacituzumab govitecan, as a single agent in two Phase 2 studies in patients with persistent or recurrent endometrial and cervical cancers. “The treatment of advanced/metastatic endometrial and cervical cancers is challenging and therapeutic options for these patien
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | IMMU | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
IMMU alerts
IMMU alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMMU alerts
High impacting IMMUNOMEDICS news events
Weekly update
A roundup of the hottest topics
IMMU
NEWS
NEWS
- Immunomedics, Inc. (NASDAQ: IMMU) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating.[MarketBeat]
- Biotech Stocks: Niche Operators Scientifically, Competing Directly As Investments [Seeking Alpha][Seeking Alpha]
- Immunomedics, Inc. (NASDAQ: IMMU) is now covered by analysts at Guggenheim. They set a "buy" rating and a $33.00 price target on the stock.[MarketBeat]
- Immunomedics, Inc. (NASDAQ: IMMU) is now covered by analysts at Goldman Sachs Group Inc. They set a "buy" rating and a $36.00 price target on the stock.[MarketBeat]
- Immunomedics, Inc. (NASDAQ: IMMU) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating.[MarketBeat]
- More
IMMU
SEC Filings
SEC Filings
- 10/3/18 - Form 8-K
- 9/28/18 - Form 8-K
- 9/27/18 - Form 3
- IMMU's page on the SEC website
- More